Progressive emergence of an oseltamivir‐resistant A(H3N2) virus over two courses of oseltamivir treatment in an immunocompromised paediatric patient

Influenza and Other Respiratory Viruses

Aeron C. Hurt²  Sook Kwan Leang²  Karin Tiedemann¹  Jeff Butler²  Francoise Mechinaud¹  Anne Kelso²  Peter Downie¹ 

[1] Children's Cancer Centre, Royal Children's Hospital, Melbourne, Vic., Australia;WHO Collaborating Centre for Reference and Research on Influenza, North Melbourne, Vic., Australia

关键词: E119V NA mutation;    immunocompromised;    influenza;    oseltamivir resistance;   

DOI  :  10.1111/irv.12108

来源: Wiley

【 摘 要 】

Abstract

A minor viral population of oseltamivir-resistant A(H3N2) viruses (E119V neuraminidase mutation) was selected and maintained in a continually infected immunocompromised child following initial oseltamivir treatment. A subsequent course of oseltamivir given 7 weeks later rapidly selected for the E119V variant resulting in a near-pure population of the resistant virus. The study highlights the challenges of oseltamivir treatment of immunocompromised patients that are continually shedding virus and demonstrates the ability of the E119V oseltamivir-resistant virus to be maintained for prolonged periods even in the absence of drug-selective pressure.

【 授权许可】

Unknown   
© 2013 John Wiley & Sons Ltd